GGrantIndex
Sort

82,697 grants matching vaccine development

Modeling, Spatial, Statistics

$945,379
Ira M Longini · Fred Hutchinson Cancer Research Center · U54 · FY2015 · GM

Preclinical characterization of a multivalent killed Filovirus/Rabies vaccine

$945,119
Matthias Johannes Schnell · Thomas Jefferson University · R01 · FY2014 · AI

Chimeric Alphavirus Vaccines for Chikungunya

$945,118
Scott C Weaver · University Of Texas Med Br Galveston · U01 · FY2010 · AI

Self-Assembling Spike-EBR Nanoparticles as a Vaccine Platform Technology Against SARS-CoV-2 and Future Pandemic Coronaviruses

$945,000
Magnus Adrian Gero Hoffmann · J. David Gladstone Institutes · DP5 · FY2025 · OD

Targeting Feedback Circuitry for Antiviral Therapy

$944,989
Leor S Weinberger · J. David Gladstone Institutes · R01 · FY2024 · AI

Modulation of the immune response to B cell lineage-based immunization by other immune interventions administered in infancy

$944,979
Genevieve Giny Fouda Amou Ou · Weill Medical Coll Of Cornell Univ · P01 · FY2025 · AI

Biocontainment Research Support Service(s) Core

$944,931
Rachel M Olson · University Of Missouri-Columbia · UC7 · FY2023 · AI

Task V34: Master Cell Banks Manufacturing for Next Generation SARS-CoV-2 Vaccines

$944,900
Heidi Trusheim · Idt Biologika Gmbh · N01 · FY2024 · AI

NSF Convergence Accelerator - Track D: Data-Driven Disease Control and Prevention in Veterinary Health

$944,875
Beatriz Martinez Lopez · University Of California-Davis · · FY2020 · TIP

Antibody Based Therapeuticcs for Chikungunya Virus

$944,844
Michael S. Diamond · Washington University · R01 · FY2012 · AI

A NOVEL, LOGICAL APPROACH TO HIV VACCINE DEVELOPMENT

$944,842
University Of Wisconsin Madison · R01 · FY2002 · AI

Baylor College of Medicine Clinical Trial Unit

$944,697
William Thomas Shearer · Baylor College Of Medicine · UM1 · FY2013 · AI

Vaccine Development for Oral Carcinoma

$944,598
University Of Pittsburgh At Pittsburgh · P01 · FY2003 · DE

Phase I Trial to Evaluate Cytomegalovirus Therapeutics - VTEU

$944,454
Mark Joseph Mulligan · Emory University · N01 · FY2014 · AI

Personalized Cystic Fibrosis Therapy and Research Center

$944,438
Anjaparavanda P Naren · Cincinnati Childrens Hosp Med Ctr · P30 · FY2024 · DK

Fox COBRE Phase II Admin Core

$944,312
Joseph M Fox · University Of Delaware · P20 · FY2023 · GM

Structure-Based Design of Drugs for Target

$944,198
Rutgers The St Univ Of Nj New Brunswick · P01 · FY2002 · GM

Develop, Optimize and Commercialize UltraMarathonRT: A new enzyme for unbiased transcriptomic and epitranscriptomic characterization of RNAs regardless of length or composition.

$944,054
Li-Tao Guo · Rnaconnect Inc · R44 · FY2025 · GM

Novel vaccine strategies to induce V2 apex-directed broad neutralizing antibodies

$943,932
Laurent Karl Verkoczy · San Diego Biomedical Research Institute · R01 · FY2019 · AI

A Novel, Logical Approach to HIV Vaccine Development

$943,623
David I Watkins · University Of Wisconsin-Madison · R01 · FY2008 · AI

Structural studies of native-like SOSIP trimers

$943,450
Ian A Wilson · Weill Medical Coll Of Cornell Univ · P01 · FY2019 · AI

Therapeutic Use of an Enhanced Form of CD4-Ig

$943,250
Michael R. Farzan · Scripps Florida · R37 · FY2018 · AI

An Orally Delivered Booster Vaccine Candidate for Hepatitis B

$943,211
John A. Howard · Applied Biotechnology Institute · R44 · FY2012 · AI

Global Analysis of Cellular Networks Involved In Restriction of HIV Replication

$943,141
Sumit K Chanda · Salk Institute For Biological Studies · P01 · FY2012 · AI

Spherical Nucleic Acid nano-architectures as first-in-class cGAS agonists for the immunotherapeutic treatment of Glioblastoma.

$943,101
Alexander H. Stegh · Washington University · R01 · FY2025 · CA